Current Vaccine Recomendations
9 October 2026
The AIVC met in October 2026 and recommended that the following viruses for vaccines used in Australia for the 2027 southern hemisphere trivalent influenza vaccines in Australia:
Egg-based vaccines:
Cell culture-, recombinant protein- or nucleic acid-based vaccines
Candidate Vaccine Viruses (CVV) recommended may differ for egg- and cell-based vaccines. In some instances, the same virus is not ideal for both production systems. When this is the case, different viruses with similar properties are selected as the prototypes to help timely vaccine production. More information is available in the Frequently asked Questions (WHO).
The AIVC recommendation for the composition of influenza vaccines for Australia in 2027 aligns with the recommendations for the 2026/27 northern hemisphere recommendation. However, it differs from the 2026 southern hemisphere with the inclusion of 2 new strains for the A(H3N2) and B Victoria lineage virus component. The recommendation made by AIVC aligns with the WHO recommendations (Recommendations announced for influenza vaccine composition for the 2027 southern hemisphere influenza season). Refer to the TGA website for further information
25 September 2026
WHO recommends that vaccines for use in the 2027 southern hemisphere influenza season contain the following:
Egg-based vaccines:
Cell culture-, recombinant protein- or nucleic acid-based vaccines